Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 8, 2021updated 01 Nov 2021 7:32am

Illumina and R-Pharm receive device registration for sequencing platforms

Illumina and R-Pharm have obtained medical device registration for two complete in vitro diagnostic (IVD) sequencing platforms in Russia.

Illumina and R-Pharm have obtained medical device registration for two complete in vitro diagnostic (IVD) sequencing platforms in Russia.

They include the NextSeq 550Dx sequencing platform, associated reagent kits, and reagents for the MiSeq Dx sequencer, which was earlier approved in the country.

The regulatory process was led by R-Pharm, Illumina’s strategic partner in Russia and the Commonwealth of Independent States. It the first approval of complete sets of sequencing instruments and reagents.

The sequencing platforms and reagents require separate approvals from the Russian medical device regulatory agency, Roszdravnadzor.

Illumina Europe Middle East and Africa senior vice-president and general manager Paula Dowdy said: “Having the two IVD-platforms available to assay developers to expand the clinical use of next-generation sequencing-based (NGS) molecular diagnostics will be a great boost to testing for genetic diseases and oncology in Russia.

“The NextSeq 550Dx is ideal for high throughput sequencing at large, federal hospitals, and the desktop MiSeqDx is well suited to the laboratory facilities of standard clinical centres.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The registrations in Russia will accelerate the expansion of the company’s sequencing-based clinical diagnostics across the country.

The company said that the IVD-ready sequencing platforms are available to customers, as well as the third-party developers to create diagnostic solutions using the technology.

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology deputy director-general Mikhail Maschan said: “These registrations are a significant step in bringing NGS technologies closer to patients, many of whom live near the smaller municipal and regional clinics. Bringing NGS diagnostics with accurate and validated results will be a huge benefit to patients.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy